Binding molecule could improve injected radiotherapy

Actinium-225 is highly promising for use in Targeted Alpha Therapy owing to its 10-day half-life, which is compatible with antibody-based targets, and its high-energy, short-distance alpha emissions that are extremely lethal to cancer cells while largely sparing surrounding cells.
Cornell Chronicle

Leave a Reply

  • (will not be published)

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>